Antibody and immune memory persistence after vaccination of preadolescents with low doses of recombinant hepatitis B vaccine

Human Vaccines

Volumn 6, Issue 2, 2010, Pages 212-218

  Gilca, Vladimir ^a   De Serres, Gaston ^a   Boulianne, Nicole ^a   De Wals, Philippe ^a   Murphy, Donald ^b   Trudeau, Gisele ^c   Deceuninck, Genevieve ^e   Massé, Richard ^d   Duval, Bernard ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^c Direction Régionale de Santé Publique de la Capitale Nationale   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antibody persistence; Booster; Hepatitis B; Immune memory; Vaccination

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; IMMUNITY; IMMUNOLOGICAL MEMORY; LOW DRUG DOSE; MALE; SCHOOL CHILD; VACCINATION;

ADOLESCENT; CHILD; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; MALE; TIME FACTORS; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 77953648106     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.2.10299     Document Type: Article

References (19)

1. Plotkin SA, Orenstein WA, Offit PA. Vaccines. Fifth Edition ed, ed. A.P.a.W.A.O. Stanley. Philadelphia: Saunders Elsevier 2008; 1725.
2. European, Consensus and Group, Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-5.
3. Petersen KM, Bulkow LR, McMahon BJ, Zanis C, Getty M, Peters H, et al. Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth. Pediatr Infect Dis J 2004; 23:650-5.
4. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25:8085-90.
5. Hammitt LL, Hennessy TW, Fiore AE, Zanis C, Hummel KB, Dunaway E, et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 2007; 25:6958-64.
6. Dentinger CM, McMahon BJ, Butler JC, Dunaway CE, Zanis CL, Bulkow LR, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J 2005; 24:786-92.
7. Kao JT, Wang JH, Hung CH, Yen YH, Hung SF, Hu TH, et al. Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine 2009; 27:1858-62.
8. Fitzsimons D, Francois G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis B vaccine, booster policy and impact of hepatitis B virus mutants. Vaccine 2005; 23:4158-66.
9. Duval B, Gilca V, Boulianne N, De Wals P, Masse R, Trudeau G, et al. Comparative long term immunogenicity of two recombinant hepatitis B vaccines and the effect of a booster dose given after five years in a low endemicity country. Pediatr Infect Dis J 2005; 24:213-8.
10. Gabbuti A, Romano L, Blanc P, Meacci F, Amendola A, Mele A, et al. Long-term immunogenicity of hepatitis B vaccination in a cohort of Italian healthy adolescents. Vaccine 2007; 25:3129-32.
11. Duval B, Boulianne N, De Serres G, Laflamme N, De Wals P, Massé R, et al. Comparative immunogenicity under field conditions of two recombinant hepatitis B vaccines in 8-10-year-old children. Vaccine 2000; 18:1467-72.
12. Da Villa G, Peluso F, Picciotto L, Bencivenga M, Elia S, Pelliccia MG. Persistence of anti-HBs in children vaccinated against viral hepatitis B in the first year of life: follow-up at 5 and 10 years. Vaccine 1996; 14:1503-5.
13. Da Villa G, Pelliccia MG, Peluso F, Ricciardi E, Sepe A. Anti-HBs responses in children vaccinated with different schedules of either plasma-derived or HBV DNA recombinant vaccine. Res Virol 1997; 148:109-14.
14. th edition. Ottawa: Public Health Agency of Canada 2006; 372.
15. Faustini A, Franco E, Sangalli M, Spadea T, Calabrese RM, Cauletti M, et al. Persistence of anti-HBs 5 years after the introduction of routine infant and adolescent vaccination in Italy. Vaccine 2001; 19:2812-8.
16. Jilg W, Schmidt M, Zachoval R, Deinhardt F. Persistence of antibodies against hepatitis B surface antigen after vaccination against hepatitis B. Dtsch Med Wschr 1985; 110:205-9.
17. Zanetti AR, Mariano A, Romano L, D'Amelio R, Chironna M, Coppola RC, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005; 366:1379-84.
18. Samandari T, Fiore AE, Negus S, Williams JL, Kuhnert W, McMahon BJ, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 2007; 120:373-81.
19. Gilca V, De Serres G, Boulianne N, De Wals P, Trudeau G, Masse R, et al. Antibody kinetics among 8-10 years old respondents to hepatitis B vaccination in a low endemic country and the effect of a booster dose given five or ten years later. Vaccine 2009; 27:6048-53.